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Compare trial: Updated data
To the Editor:
In 2006, our article ‘‘A randomised trial to compare the
pharmacokinetic, pharmacodynamic and antiviral eﬀects
of peginterferon alfa-2b and peginterferon alfa-2a in pa-
tients with chronic hepatitis C (COMPARE),” which
was an 8-week comparison of peginterferon alfa-2a and
peginterferon alfa-2b, was published in the Journal of
Hepatology [1].
In COMPARE and other Schering-Plough-supported
trials, Schering-Plough used a proprietary quantitative
TaqMan PCR assay to quantify hepatitis C virus (HCV)-
RNA levels. In early 2007, Schering-Plough discovered
that, in some instances, this assay yielded incorrect HCV-
RNA levels. The COMPARE study was aﬀected by the
assay inaccuracies, and certain samples from patients
enrolled in these studies required reanalysis. Samples iden-
tiﬁed as having been measured incorrectly have since been
reanalyzed, andwe can conﬁrm that the overall conclusions
reported in our published article remain unchanged.
Although the overall conclusions of this publication
remain unchanged, some of the data were adjusted.
Brieﬂy, all values presented in Table 3 in the article were
adjusted slightly; however, the adjustments did not result
in any change in the statistical signiﬁcance between
peginterferon alfa-2a and peginterferon alfa-2b. The
reanalysis data indicate that the average decrease in
HCV-RNA and the mean maximum decrease in HCV-
RNA are signiﬁcantly greater among patients receiving
peginterferon alfa-2b than among those receiving pegin-
terferon alfa-2a at week 1 (P < .05 for both comparisons)
and week 4 (P < .0001 for both comparisons). In addi-
tion, at week 4, the number of patients receiving peginter-
feron alfa-2a is reduced from 18 to 17, and the number
receiving peginterferon alfa-2b is reduced from 18 to 16.
Peginterferon alfa-2a versus peginterferon alfa-2b data
did not change, but correlation coeﬃcients and probabili-
ties for the week 8 carry-forward response (W8cfresp) data
for cyclin D, IP10, ISG15, ISG54, perforin, PKR, signal
transducer and activator of transcription (STAT)-1,
STAT-2, and 2050 OASwere aﬀected (Table 4 in the article).
For each of these transcripts, the reanalysis indicated a re-
duced Spearman correlation coeﬃcient compared with the
original data. Similar changes were noted for theW8cfresp
data in Table 5 in the article, resulting in a reduced correla-
tion coeﬃcient for principle component (Prin) 1 and Prin2,
an increased correlation coeﬃcient for Prin3, and a nega-
tive correlation at Prin4 and Prin5 compared with the ori-
ginal data. The reanalysis indicated that the diﬀerences in
gene transcript levels between responders and non-
responders for inducible protein 10 (IP10) and RNA-
dependent protein kinase (PKR) (maximum fold increase
from baseline;Cmax) and IP10, PKR, and interferon-stim-
ulated gene (ISG) 54 (area under the curve; AUC) re-
mained statistically signiﬁcant (P < .05) (Table 2 in the
article). The diﬀerences in ISG15, 2050 oligoadenylate syn-
thetase (OAS), and ISG54 (Cmax) and ISG15 and 2
050
OAS (AUC) between responders and non-responders that
were statistically signiﬁcant in the original analysis were no
longer signiﬁcant (Table 2 in the article).
All the data presented in Figs. 4A and B in the article
were slightly aﬀected. For peginterferon alfa-2a, the dif-
ference in mean AUC of IP10 between responders and
non-responders remained statistically signiﬁcant; how-
ever, for peginterferon alfa-2b, the diﬀerence in mean
AUC for ISG54 between responders and non-responders
failed to reach statistical signiﬁcance using the reanalysis
data (Fig. 4A). In the reanalysis, a patient previously con-
sidered a responderwas reclassiﬁed as a non-responder: in
the reanalysis, 9 of 14 patients were responders and 5were
non-responders (Fig. 4B in the article). Data presented in
Fig. 5 in the article were slightly aﬀected; however, the
mean maximal log10 change in HCV-RNA from baseline
remained signiﬁcantly greater among patients receiving
peginterferon alfa-2b than among those receiving pegin-
terferon alfa-2a at week 1 and week 4 (P < .05) for both
comparisons. Finally, the data presented in Fig. 6 in the
article were also slightly aﬀected; however, the rate of de-
cline in HCV-RNA during the 8 weeks of treatment re-
mained signiﬁcantly greater among patients receiving
peginterferon alfa-2b than among patients receiving
peginterferon alfa-2a.
As stated, the adjustments noted above did not
change the overall conclusions reported in our published
article. However, we believe that full disclosure of the
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assay inaccuracies, the subsequent reanalysis, and
results of the reanalysis were imperative to communicate
to the medical community.
Appendix A. Supplementary data
Supplementary data associated with this article can
be found, in the online version, at doi:10.1016/j.jhep.
2008.05.009.
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Spanish reports of hepatotoxicity associated with Herbalife products
To the Editor:
We have read with interest the articles recently pub-
lished in this journal by Elinav et al. [1] and Schoepfer
et al. [2], as well as the editorial by Stickel [3], reporting
and discussing two series of cases from Israel and Swit-
zerland of hepatotoxicity associated with the consump-
tion of Herbalife slimming products. Stickel [3] raises
the question of why products which are distributed in
at least 60 countries only seem to induce hepatotoxicity
in two.
In Spain, as perhaps in other countries, Herbalife
distributes its products through door-to-door salesmen
and the internet. Some products are registered as dietetic
supplements, but others are not registered at all. In
2005, three cases of hepatotoxicity (two hepatitis and
one of increased liver enzymes) were reported to the
Pharmacovigilance Centre of Asturias, an area in the
north of Spain. Another case of increased liver enzymes
was reported in 2006. All the four cases occurred in wo-
men between 47 and 57 years old, and all came from the
same hospital. Three of these were published last Febru-
ary in a Spanish medical journal [4].
In the two cases of hepatitis the patients were sisters.
One of whom developed severe liver damage. After tak-
ing Herbalife products for 1 year and losing 20 kg in
weight, she was referred to hospital suﬀering from wide-
spread pruritus, jaundice, fatigue and abdominal strain.
Biochemical tests showed liver transaminases over
1000 U/l and 12 mg/dl of total bilirubin. Test antibodies
to hepatitis were negative. Abdominal ultrasound
showed a cholelithiasis that was surgically removed.
Although she was recommended to cease taking Herba-
life products, she continued to do so for another 2
years and developed chronic liver disease with recurrent
exacerbations. Liver biopsy showed acute hepatitis
grade 4 on chronic liver disease stage 3. She was diag-
nosed as having idiopathic or toxic autoimmune hepati-
tis, and is currently being treated with corticosteroids.
Her sister took Herbalife products for six months
and developed diarrhea, hyperbilirubinemia, jaundice
and pruritus. Biochemical tests showed transaminases
over 1000 U/l and 26.7 mg/dl of total bilirubin. Viral
antibodies were negative. Subacute cholestatic hepatitis
was diagnosed and the withdrawal of Herbalife prod-
ucts was recommended. Some months later, the patient
had totally recovered. The two sisters took the following
Herbalife products: formulas 1, 2, 3 and 4, RoseOx,
Herbalifeline, Guarana´, Classic Aromatized Tea and
Herbal Aloe.
The patients in the other two cases of reported hepa-
totoxicity were also taking Herbalife products over a
period of 1 month in one case and 3 years in the other,
and developed increased transaminases which were de-
tected on routine analysis. After the withdrawal of Her-
balife products, the enzyme levels returned to normal.
To explain the mechanism involved in the hepatotox-
icity induced by Herbalife products, Elinav et al. [1]
have suggested genetic susceptibility to develop an im-
mune-mediated liver toxicity associated with one or
more constituents. The family ties between the two cases
of hepatitis reported in Spain and the diagnosis of auto-
immune hepatitis in one case support this observation.
We agree with Stickel [3] when he explains that it is ex-
tremely diﬃcult to identify the crucial compounds when
consumers of Herbalife are taking several products.
Although toxic or bacteriological contamination of
some batches cannot be dismissed, we believe that some
components of Herbalife products could be the hepa-
toxicity inducers. Firstly, as Schoepfer et al. [2] have
suggested, the green tea contained in the Classic Aroma-
tized Tea and also in other Herbalife products. In the
last 5 years, evidence on the ability of green tea to induce
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